Yong Chang Lin

US Patent:

20100196885, Aug 5, 2010

Filed:

Jan 22, 2008

Appl. No.:

12/449124

Inventors:

Gerard M. Turino - New York NY, US
Yong Y. Lin - Bridgewater NJ, US
Shuren Ma - Cliffside Park NJ, US
Seymour Lieberman - New York NY, US

International Classification:

C12Q 1/68
C12Q 1/00
G01N 33/00
C12Q 1/02

US Classification:

435 6, 435 4, 436 96, 435 29

Abstract:

The present invention relates to methods of diagnosing and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.

US Patent:

20130273586, Oct 17, 2013

Filed:

Mar 15, 2013

Appl. No.:

13/836332

Inventors:

Shuren Ma - Cliffside Park NJ, US
Yong Y. Lin - Bridgewater NJ, US
Seymour Leiberman - New York NY, US

International Classification:

G01N 27/62

US Classification:

435 23, 436 96, 435 29

Abstract:

The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.

US Patent:

20190100585, Apr 4, 2019

Filed:

Mar 7, 2017

Appl. No.:

16/082841

Inventors:

- Paris, FR
- Tarrytown NY, US
Neil GRAHAM - Tarrytown NY, US
Yong LIN - Bridgewater NJ, US
Janie PARRINO - Tarrytown NY, US
Rahul PATEL - Bridgewater NJ, US
Janet VAN ADELSBERG - New York NY, US
Hubert VAN HOOGSTRATEN - Bridgewater NJ, US

International Classification:

C07K 16/24
A61P 19/02
C07K 16/28
A61K 39/395

Abstract:

The present invention relates to the use of an anti-IL6 receptor antibody in monotherapy for treating rheumatoid arthritis and for improving the physical function and the quality of life of a subject suffering from rheumatoid arthritis.

US Patent:

20180172705, Jun 21, 2018

Filed:

Feb 5, 2018

Appl. No.:

15/888959

Inventors:

- New York NY, US
Shuren Ma - Cliffside Park NJ, US
Yong Y. Lin - Bridgewater NJ, US
Seymour Leiberman - , US

International Classification:

G01N 33/68
H01J 49/00
G01N 27/62
G01N 30/72

Abstract:

The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.

US Patent:

20150355193, Dec 10, 2015

Filed:

May 14, 2015

Appl. No.:

14/712811

Inventors:

- New York NY, US
Shuren Ma - Cliffside Park NJ, US
Yong Y Lin - Bridgewater NJ, US
Seymour Leiberman - , US

International Classification:

G01N 33/68
G01N 30/72
H01J 49/00

Abstract:

The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.